ReviewMedGenMed : Medscape general medicine2005
Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature.
Review in MedGenMed : Medscape general medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 38 citations in OpenAlex.
- COVID-19-associated opportunistic infections: a snapshot on the current reports.Clinical and experimental medicine · 2022Review
- Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease.IDCases · 2019Article
- Granulomatous response to invasive pulmonary aspergillosis in an immunotherapy-naive host, a maladaptive response?Respiratory medicine case reports · 2018Article
- Disseminated aspergillosis causing intestinal failure following colectomy for perforated colitis.Frontline gastroenterology · 2016Article
- Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.Annals of the rheumatic diseases · 2014Article
- Mucormycosis in patients with inflammatory bowel disease: case series and review of the literature.Case reports in medicine · 2014Article
- The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.Digestive diseases and sciences · 2013Review
- Disseminated Aspergillosis due to Aspergillus niger in Immunocompetent Patient: A Case Report.Case reports in infectious diseases · 2013Article
- Epidemiology and treatment approaches in management of invasive fungal infections.Clinical epidemiology · 2011Article
- Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2010Article
- Infliximab in the treatment of Crohn's disease.Therapeutics and clinical risk management · 2007Article
- Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus.Antimicrobial agents and chemotherapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 55-year-old white woman with a greater than 25-year history of Crohn's disease developed disseminated aspergillosis following combination therapy with Methylprednisolone, azathioprine, and infliximab. The patient was hospitalized 11 days after initiation of infliximab for respiratory symptoms and developed respiratory failure, coma, and died. Postmortem examination revealed disseminated Aspergillus fumigatus involving multiple organs. This case demonstrates that combined treatment with infliximab, methylprednisone, and azathioprine may induce severe immunosuppression and depressed cellular immunity, leading to severe opportunistic infections. Given the increasing use of antitumor necrosis factor agents, physicians should be aware of the risk of opportunistic infections and be vigilant about diagnosing and aggressively treating these infections to reduce the risk of disseminated disease.
Indexed as
Identifiers
16369233PMC1681636W1503776683What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.